57883-25-7

Basic information

• Product Name: 3-BROMO-2-ETHOXYPYRIDINE
• Synonyms: 3-BROMO-2-ETHOXYPYRIDINE;2-Ethoxy-3-Bromopyridine
• CAS NO: 57883-25-7
• Molecular Formula: C₇H₈BrNO
• Molecular Weight: 202.04852
• Product Categories: Pyridine
• Mol File: 57883-25-7.mol

Chemical Properties

• Boiling Point: 210.307 °C at 760 mmHg
• Flash Point: 80.991 °C
• Appearance: yellow liquid
• Density: 1.45 g/cm³
• Vapor Pressure: 0.28mmHg at 25°C
• Refractive Index: 1.5450 to 1.5490
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.68±0.22(Predicted)
• CAS DataBase Reference: 3-BROMO-2-ETHOXYPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-2-ETHOXYPYRIDINE(57883-25-7)
• EPA Substance Registry System: 3-BROMO-2-ETHOXYPYRIDINE(57883-25-7)

Safety Data

• Hazardous Substances Data: 57883-25-7(Hazardous Substances Data)

Usage

Uses

Used in Agrochemical Industry:
3-BROMO-2-ETHOXYPYRIDINE is used as a key intermediate for the development of new agrochemicals, specifically in the creation of pesticides and other compounds that help protect crops from pests and diseases.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 3-BROMO-2-ETHOXYPYRIDINE serves as an essential building block for the synthesis of various drugs. Its unique structure allows for the development of molecules with specific therapeutic properties, contributing to the advancement of medicinal chemistry.
Used in Dye Industry:
3-BROMO-2-ETHOXYPYRIDINE is also utilized as an intermediate in the production of dyes. Its chemical structure enables the creation of dyes with specific color properties, making it a valuable component in the formulation of a wide range of colorants for various applications.

InChI:InChI=1/C7H8BrNO/c1-2-10-7-6(8)4-3-5-9-7/h3-5H,2H2,1H3

Upstream product

• 13534-89-9 2,3-dibromopyridine 
• 64-17-5 ethanol 
• 52200-48-3 3-bromo-2-chloropyridine 
• 141-52-6 sodium ethanolate 
• 36178-05-9 3-bromo-2-fluoropyridine 

Downstream Products

• 1445862-54-3 4-(3-chloro-4-ethylphenoxy)-3-(2-ethoxypyridin-3-yl)-N-(methylsulfonyl)benzamide diethylamine salt 
• 1445862-63-4 4-[3-chloro-4-(trifluoromethoxy)phenoxy]-5-(2-ethoxypyridin-3-yl)-2-fluoro-N-(methylsulfonyl)benzamide 
• 1445862-55-4 4-[4-chloro-3-(trifluoromethyl)phenoxy]-3-(2-ethoxypyridin-3-yl)-N-(methylsulfonyl)benzamide 
• 1445862-74-7 4-(3-chloro-4-ethylphenoxy)-3-(2-ethoxypyridin-3-yl)benzaldehyde 
• 1445862-75-8 4-(4-chloro-3-(trifluoromethyl)phenoxy)-3-(2-ethoxypyridin-3-yl)benzaldehyde 
• 1445862-77-0 4-(3-chloro-4-(trifluoromethyl)phenoxy)-3-(2-ethoxypyridin-3-yl)benzaldehyde 
• 1445862-81-6 3-(2-ethoxypyridin-3-yl)-4-fluorobenzaldehyde 
• 1445862-79-2 3-(2-ethoxypyridin-3-yl)-4-(4-(trifluoromethoxy)phenoxy)benzaldehyde 
• 1445862-80-5 4-(3-chloro-4-(trifluoromethoxy)phenoxy)-3-(2-ethoxypyridin-3-yl)benzaldehyde 
• 1445862-60-1 4-[3-chloro-4-(trifluoromethoxy)phenoxy]-3-(2-ethoxypyridin-3-yl)-N-(methylsulfonyl)benzamide 
• 1445862-61-2 3-(2-ethoxypyridin-3-yl)-N-(methylsulfonyl)-4-(4-(trifluoromethoxy)phenoxy)benzamide 
• 848243-23-2 2-ethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 851773-43-8 (2-ethoxypyridin-3-yl)methanamine 
• 14248-71-6 2-ethoxynicotinonitrile 

Relevant articles and documents

Regioselective Amination or Alkoxylation of Halogenated Amino-, Thio- or Alkoxypyridines via Pyridyne Intermediates

The treatment of 3-halopyridines (Cl, Br) bearing an R-substituent in position 2 (R = OEt, NEt2, N-piperidyl, or SEt) or in position 5 (R = OMe, OEt, SEt, NMe2, NEt2, or aryl) with KHMDS and an amine at 25 C for 12 hours in THF provided regioselectively 3

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

MACROCYCLES AS PDE1 INHIBITORS

The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to substituted triazolopyridine compounds of general formula (I); in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

SULFONAMIDE DERIVATIVES AND USE THEREOF AS VGSC INHIBITORS

The invention relates to new sulfonamide Nav1.7 inhibitors and pharmaceutically acceptable salts thereof, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. Nav1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

TRIAZOLOPYRIDINE DERIVATIVES

The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.